Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Edward John Belouski is active.

Publication


Featured researches published by Edward John Belouski.


PLOS ONE | 2015

Trefoil Factor 3 (TFF3) Is Regulated by Food Intake, Improves Glucose Tolerance and Induces Mucinous Metaplasia

Hongfei Ge; Jonitha Gardner; Xiaosu Wu; Ingrid C. Rulifson; Jinghong Wang; Yumei Xiong; Jingjing Ye; Edward John Belouski; Ping Cao; Jie Tang; Ki Jeong Lee; Suzanne Coberly; Xinle Wu; Jamila Gupte; Lynn Miao; Li Yang; Natalie Nguyen; Bei Shan; Wen-Chen Yeh; Murielle M. Véniant; Yang Li; Helene Baribault

Trefoil factor 3 (TFF3), also called intestinal trefoil factor or Itf, is a 59 amino acid peptide found as a homodimer predominantly along the gastrointestinal tract and in serum. TFF3 expression is elevated during gastrointestinal adenoma progression and has been shown to promote mucosal wound healing. Here we show that in contrast to other trefoil factor family members, TFF1 and TFF2, TFF3 is highly expressed in mouse duodenum, jejunum and ileum and that its expression is regulated by food intake. Overexpression of TFF3 using a recombinant adeno-associated virus (AAV) vector, or daily administration of recombinant TFF3 protein in vivo improved glucose tolerance in a diet-induced obesity mouse model. Body weight, fasting insulin, triglyceride, cholesterol and leptin levels were not affected by TFF3 treatment. Induction of mucinous metaplasia was observed in mice with AAV-mediated TFF3 overexpression, however, no such adverse histological effect was seen after the administration of recombinant TFF3 protein. Altogether these results suggest that the therapeutic potential of targeting TFF3 to treat T2D may be limited.


Archive | 2010

FGF21 mutants and uses thereof

Edward John Belouski; Murielle Marie Ellison; Agnes Eva Hamburger; Randy Ira Hecht; Yue-Sheng Li; Mark Leo Michaels; Jeonghoon Sun; Jing Xu


Archive | 2011

FGF21 mutant fusion polypeptides and uses thereof

Edward John Belouski; Murielle Marie Ellison; Agnes Eva Hamburger; Randy Ira Hecht; Yue-Sheng Li; Mark Leo Michaels; Jeonghoon Sun; Jing Xu


Archive | 2009

FGF21 polypeptides comprising two or more mutations

Edward John Belouski; Murielle Marie Ellison; Agnes Eva Hamburger; Randy Ira Hecht; Yue-Sheng Li; Mark Leo Michaels; Jeonghoon Sun; Jing Xu


Archive | 2011

Uses of FGF21 polypeptides comprising two or more mutations

Edward John Belouski; Murielle Marie Ellison; Agnes Eva Hamburger; Randy Ira Hecht; Yue-Sheng Li; Mark Leo Michaels; Jeonghoon Sun; Jing Xu


Archive | 2010

SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3

John K. Sullivan; Leslie P. Miranda; Colin V. Gegg; Shaw-Fen Sylvia Hu; Edward John Belouski; Justin K. Murray; Hung Nguyen; Kenneth W. Walker; Taruna Arora; Frederick W. Jacobsen; Yue-Sheng Li; Thomas C. Boone


Archive | 2016

Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods

Jeonghoon Sun; Jason C. O'neill; Randal R. Ketchem; Randy Ira Hecht; Edward John Belouski; Mark Leo Michaels


Archive | 2012

FGF 21 polypeptides comprising two or more mutations and uses thereof

Edward John Belouski; Murielle Marie Ellison; Agnes Eva Hamburger; Randy Ira Hecht; Yue-Sheng Li; Mark Leo Michaels; Jeonghoon Sun; Jing Xu


Archive | 2012

FGF21 mutants multimers and uses thereof

Edward John Belouski; Murielle Marie Ellison; Agnes Eva Hamburger; Randy Ira Hecht; Yue-Sheng Li; Mark Leo Michaels; Jeonghoon Sun; Jing Xu


Archive | 2015

BI-SPECIFIC ANTI-CGRP RECEPTOR/PAC1 RECEPTOR ANTIGEN BINDING PROTEINS AND USES THEREOF

Gunasekaran Kannan; Ling Liu; Edward John Belouski; Cen Xu

Collaboration


Dive into the Edward John Belouski's collaboration.

Researchain Logo
Decentralizing Knowledge